Clinical Trial Update: Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update: administration of allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-ischemic Dilated Cardiomyopathy

Drugs mentioned

• Allogeneic-MSC (mesenchymal stem cells)

Snippet

Sponsor: Joshua M Hare | Conditions: Non-ischemic Dilated Cardiomyopathy | Phase 2 | Status: RECRUITING